文献速递膀胱癌与上尿路尿路上皮癌

化疗消融凝胶(UGN-102)用于成人非肌层浸润性膀胱癌一线治疗的患者报告副作用极小

Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer.
PubMed 文献 · J Urol · 2022-05-31

Optima II 2b期试验评估UGN-102(含丝裂霉素的反向热凝胶)每周6次灌注作为非肌层浸润性膀胱癌主要治疗,44例完成季度患者报告结局量表,3个月时泌尿症状、腹胀/排气或不适无恶化,性功能轻度变差,未来健康担忧改善,访谈中患者认可非手术选择并愿推荐凝胶或选择凝胶而非手术。

要点

  • UGN-102每周6次灌注作为NMIBC主要治疗,3个月时患者报告泌尿症状、腹胀/排气或不适无恶化。
  • 性功能轻度变差,未来健康担忧改善,人口学特征与变化无相关性。
  • 访谈中患者认可非手术选择,愿推荐凝胶给其他患者并选择凝胶而非手术。

核心结论

  • 非手术化疗消融凝胶UGN-102作为NMIBC主要治疗,提供比标准治疗更以患者为中心的治疗方式。

研究设计与样本

  • Optima II(NCT03558503)为2b期试验,评估UGN-102作为NMIBC主要治疗的非手术替代方案。
  • 63例患者从20个中心入组,其中44例纳入完成季度患者报告结局量表的队列。
  • 44例中10例(23%)在试验后接受访谈,以了解未来患者治疗决策的耐受性。

主要发现

  • 患者报告结局队列(44例)中,61%为男性,57%年龄65岁及以上,89%为非西班牙裔白人。
  • 3个月主要终点时,UGN-102未导致患者报告泌尿症状、腹胀/排气或不适下降。
  • 性功能轻度变差,未来健康担忧改善,人口学特征与变化无相关性。
  • 临床上,性功能与新发NMIBC相关,腹胀/排气与12个月内经尿道膀胱肿瘤电切术相关。
  • 访谈中患者认可非手术替代方案,愿推荐凝胶给其他患者并选择凝胶而非手术。

关键数值与推荐

  • 患者接受6次每周UGN-102灌注,UGN-102为含丝裂霉素的反向热凝胶。
  • 副作用变化使用Wilcoxon符号秩检验评估。
  • 3个月结局与人口学及临床特征的关联使用回归分析,控制基线值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Optima II ("OPTimized Instillation of Mitomycin for Bladder Cancer Treatment," clinicaltrials.gov: NCT03558503) was a phase 2b trial evaluating a nonsurgical alternative as a primary treatment for nonmuscle-invasive bladder cancer (NMIBC). Patients received 6 weekly instillations of UGN-102, a mitomycin-containing reverse thermal gel. This is the first study to report on patient-reported side effects of UGN-102. MATERIALS AND METHODS: Sixty-three patients enrolled in Optima II from 20 sites. Of these 63 patients, 44 were in the cohort completing a quarterly patient-reported outcome measure assessing side effects. Changes in side effects were evaluated using the Wilcoxon signed-rank test. Associations of 3-month outcomes with demographic and clinical characteristics were examined with regression, controlling for baseline values. Ten of 44 patients (23%) were interviewed after the trial to understand tolerability for future patients making treatment decisions. Transcripts were double-coded using standard methods. RESULTS: In the patient-reported outcome measure cohort (44), 61% were men, 57% aged 65+ years and 89% were non-Hispanic White. UGN-102 did not cause decrements in patient-reported urinary symptoms, bloating/flatulence or malaise at the primary endpoint of 3 months. Sexual function mildly worsened. Future health worries improved. Demographics were not correlated with changes. Clinically, sexual function was correlated with new NMIBC and bloating/flatulence was associated with transurethral resection of bladder tumor within 12 months. In interviews, patients appreciated a nonsurgical alternative, would recommend the gel to other patients and would choose the gel over surgery. CONCLUSIONS: A nonsurgical, chemoablative gel (UGN-102) used as a primary treatment for NMIBC offers a more patient-centered therapeutic approach than standard treatments.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Stover AM, Basak R, Mueller D, et al. Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer. J Urol. 2022. PMID: 35640276. doi:10.1097/JU.0000000000002747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。